Next Article in Journal
Double Variational Binding—(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands
Next Article in Special Issue
Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy
Previous Article in Journal
Intracellular Delivery of Molecular Cargo Using Cell-Penetrating Peptides and the Combination Strategies
Previous Article in Special Issue
Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(8), 19537-19552;

Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection

Huron Peak Ave., Superior, CO 80027, USA
Allevagen, LLC, 4105 Perry St., Denver, CO 80212, USA
Author to whom correspondence should be addressed.
Academic Editor: Tatsuo Kanda
Received: 1 June 2015 / Revised: 5 August 2015 / Accepted: 7 August 2015 / Published: 18 August 2015
(This article belongs to the Special Issue Viral Hepatitis Research)
Full-Text   |   PDF [1061 KB, uploaded 18 August 2015]   |  


Chronic hepatitis delta virus infection (CHD) is a condition arising from super-infection of hepatitis B virus (HBV)-infected patients, resulting in a more rapid advance in liver pathology and hepatocellular carcinoma than is observed for HBV mono-infection. Although hepatitis delta virus (HDV) is structurally simple, its life cycle involves the complex participation of host enzymes, HBV-derived surface antigen (HBsAg), and HDV-auto-ribozyme and hepatitis delta antigen (HDAg) activities. Unsatisfactory clinical trial results with interferon-based therapies are motivating researchers to adjust and redirect the approach to CHD drug development. This new effort will likely require additional structural and functional studies of the viral and cellular/host components involved in the HDV replication cycle. This review highlights recent work aimed at new drug interventions for CHD, with interpretation of key pre-clinical- and clinical trial outcomes and a discussion of promising new technological approaches to antiviral drug design. View Full-Text
Keywords: HDV; HBV; HIV; deltavirus; hepatitis; therapeutic; clinical; trial HDV; HBV; HIV; deltavirus; hepatitis; therapeutic; clinical; trial

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Guo, Z.; King, T. Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection. Int. J. Mol. Sci. 2015, 16, 19537-19552.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top